The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance.

• Authors: HÁJEK Roman; ZAHRADOVÁ Lenka; GREGORA Evžen; SCHÜTZOVÁ Miroslava; KOZA Vladimír; PAVLÍČEK Petr; POUR Luděk; KREJČÍ Marta; SANDECKÁ Viera; KŘIVANOVÁ Andrea; AL-SAHMANI Mohamed Abdo Saleh; KRÁLOVÁ Dana; ADAM Zdeněk
• Year of publication: 2008
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: In this trial, we have evaluated the potential of combinative regimen CVD (Cyclophosphamide, Bortezomib (Velcade), Dexamethasone) reduced intensity (CVD senior; 50% reduction) in elderly pts and/or pts with poor status performance with relapsed MM. The results were compared with CVD junior regimen outcome used at the same time in pts aged < 65 years and good status performance. The reduced CVD senior regimen is tolerated better than CVD junior. Duration of treatment and number of cycles was similar in both regimens. There was no difference in overall response but the higher total dose of bortezomib achieved by pts in each group resulted in a better response in both groups. The reduced intensity CVD regimen seems to be a good option for elderly pts with poor status performance with well balanced efficacy/toxicity ratio.